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Introduction: Haematological malignancies originate and progress in primary and secondary 
lymphoid organs, where they establish a uniquely immune-suppressive tumour 
microenvironment. Although high-throughput transcriptomic and proteomic approaches are 
being employed to interrogate immune surveillance and escape mechanisms in patients with 
solid tumours, and to identify actionable targets for immunotherapy, our knowledge of the 
immunological landscape of haematological malignancies, as well as our understanding of the 
molecular circuits that underpin the establishment of immune tolerance, is not comprehensive. 
Areas covered: This article will discuss how multiplexed immunohistochemistry, flow 
cytometry/mass cytometry, proteomic and genomic techniques can be used to dynamically 
capture the complexity of tumour-immune interactions. Moreover, the analysis of multi-
dimensional, clinically annotated data sets obtained from public repositories such as Array 
Express, TCGA and GEO is crucial to identify immune biomarkers, to inform the rational 
design of immune therapies and to predict clinical benefit in individual patients. We will also 
highlight how artificial neural network models and alternative methodologies integrating other 
algorithms can support the identification of key molecular drivers of immune dysfunction. 
Expert comment: High-dimensional technologies have the potential to enhance our 
understanding of immune-cancer interactions and will support clinical decision making and the 
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1. Introduction 
Tumours are organised tissues that are infiltrated with immune cell populations of both the 
lymphoid and myeloid lineage [1] and possess both tumour-promoting and tumour-inhibiting 
properties. Compelling evidence indicates that pre-existing immunological features contribute 
to the ability of patients with solid tumours to respond to immunotherapy with 
immunomodulatory agents such as checkpoint inhibitors [2]. The Immune Biomarkers Task 
Force of the Society for Immunotherapy of Cancer (SITC) recently published 
recommendations on the discovery of immune-related biomarkers, in which it highlighted the 
complexity of the tumour microenvironment (TME) and discussed novel tools to analyse the 
diversity of immune genes, proteins, cells and pathways [3]. A broader understanding of 
baseline immunity, both in the periphery and in the TME, and of immune escape mechanisms 
is likely to expedite the identification of biomarkers that are predictive of clinical outcome and 
elucidate why cancer patients might fail to respond to immunotherapy [4,5]. Powerful 
technologies such as genome-wide association studies (GWAS), multiplexed 
immunohistochemistry, high-dimensional blood profiling of immune cells by flow cytometry 
and mass cytometry are increasingly being integrated in this nascent, but rapidly evolving 
field. The aim of these approaches is to assess immune competence and the likelihood of 
patients with solid tumours to respond to immunotherapy. In general, tumour infiltration by 
leukocyte subsets such as CD8+ T cells and CD45RO+ memory T cells with specific gene 
signatures and increased B-cell receptor (BCR) diversity is associated with an improved 
overall survival (OS), as has been demonstrated by mRNA sequencing data from The Cancer 
Genome Atlas (TCGA) in 11 solid tumour types encompassing breast, lung, melanoma and 
lung adenocarcinoma and representing 3,485 patients [6]. In contrast, macrophage signatures 
predicted poorer survival in most tumour types. The presence of T-cell infiltration contributes 
to a higher “immunoscore” in patients with colorectal cancer (CRC), which correlates with 
improved patient prognosis [7]. 
Whereas the role of anti-tumour immunity in shaping clinical responses to therapy has been 
thoroughly investigated in melanoma and CRC, our understanding of the role played by 
individual immune cell types in the control of haematological malignancies remains limited. In 
principle, haematological malignancies are amenable to immune-mediated therapeutic 
effects, as suggested by the curative potential of allogeneic haematopoietic stem cell 
transplantation (HSCT). Although immune checkpoint blockade has only been pursued 
recently in patients with Hodgkin and non-Hodgkin lymphoma [8,9], the field is expected to 
advance exponentially, as has already occurred in solid tumour oncology. This will entail a 
paradigm shift in our current treatment modalities. An imperative for the correct design of 
clinical trials would be to dissect the determinants of response and resistance to checkpoint 
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blockade and to decipher the architecture and composition of the TME, as well as the 
functional orientation of peripheral blood immune cells in patients with leukaemia, lymphoma 
and multiple myeloma (MM). Challenges to identifying biomarkers have recently been 
reviewed [10]. Despite the reciprocal relationship between tumours and the patient’s immune 
system, it is presently unknown whether measurements in blood may correlate with findings 
from tumour sites, including lymph nodes and bone marrow (BM) [3,11]. In this respect, 
peripheral blood markers reflecting immune function at baseline (“peripheral immunoscore”) 
have successfully predicted progression-free survival (PFS) in patients receiving vaccines for 
metastatic breast cancer and prostate cancer [12]. 
This review will focus on current strategies to interrogate the immunological TME in patients 
with haematological malignancies, with the objective to subvert cancer-induced immune 
suppression and identify targets for treatment. 
 
2. Structure and function of the tumour microenvironment (TME) 
Neoplastic cells activate gene expression programmes in the TME that are supportive of 
tumour growth and inherently immune suppressive [4]. The TME is increasingly viewed as an 
attractive candidate for the discovery of predictive and prognostic immune biomarkers [11,13]. 
For instance, intra-tumoural levels of IL-15 strongly correlate with immune cell proliferation 
and disease recurrence in patients with CRC [14]. An ‘immunome’ compendium of mRNA 
transcripts specific for innate and adaptive immune cell populations has characterised the 
immune composition of the TME in CRC [15]. The patterns of gene expression were 
remarkably different in patients with significantly prolonged disease-free survival (DFS) and in 
those with unfavourable outcome. The former showed an over-representation of T-cell-related 
genes, including  T cells and cytotoxic T cells, macrophages and mast cells. Follicular helper 
T cells (Tfh) and B cells also exerted a favourable effect on patient outcome. In contrast, 
patients with poor outcomes showed an over-representation of genes specific for eosinophils, 
Th2 cells, Th17 cells, Treg cells and NK cells. Interestingly, the in situ immune reaction 
evolved with tumour progression from stages T1 to T4, with most of the T-cell markers 
decreasing with tumour stage. 
Programmed Death Ligand (PDL)-L1 is expressed by cells in the TME, engages PD1 on T 
cells and triggers inhibitory signalling which prevents T-cell effector function and cytotoxicity 
[16]. PD-L1 expression in response to cytokine stimuli, most importantly IFN-, has been 
termed ‘adaptive immune resistance’ [17]. Co-localisation of inflammatory responses with CD8 
and PD-L1 expression has been correlated with improved clinical outcome in patients with 
metastatic, but not localised, melanoma, implying that ‘inflamed’ tumours expressing PD-L1 
might be more amenable to respond to immunotherapy [17]. A pragmatic classification of solid 
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tumours based on their PD-L1 status and presence or absence of tumour-infiltrating 
lymphocytes (TILs) has been recently proposed [18]. Type I (PD-L1-expressing with TILs) and 
type II TMEs (PD-L1 negative with no pre-existing TILs) account for approximately 80% of 
human melanomas, with type I tumours having the best prognosis [17]. Other tumour types 
may exhibit a type III TME, in which constitutive PD-L1 expression is driven by oncogenic 
events rather than adaptive immune resistance, as shown in gliomas with loss of PTEN 
function [19] and in T-cell lymphomas [20]. Finally, although type IV tumours contain TILs, 
these show no expression of PD-L1, thereby suggesting a potential role for other immune 
suppressive circuits in driving immune dysfunction [18]. 
Intriguingly, three immune profiles have been revealed by clinical studies indicating that 
patients with ‘inflamed’ melanomas were more likely to respond to immunotherapy with 
checkpoint blocking agents [21,22]. The immune-inflamed phenotype is characterised by the 
presence of both CD4+ and CD8+ T cells, often accompanied by myeloid and monocytic cells, 
and by staining for PD-L1 on TILs and, in some cases, on tumour cells. The immune-excluded 
phenotype is characterised by tumours in which immune cells are retained in the stroma and 
fail to migrate and penetrate the tumour itself, and is unlikely to respond to immunotherapy. 
The third profile, the immune-desert phenotype, is characterised by a paucity of T cells, which 
is indicative of the absence of pre-existing anti-tumour immune responses, and by the 
presence of myeloid-derived suppressor cells (MDSCs), M2 macrophages and regulatory T 
(Treg) cells, which mediate immune suppression or tolerance. The importance of pre-existing, 
clonally restricted CD8 T-cell responses and of physical proximity between PD1+ and PD-L1+ 
cells in the TME for tumour regression after immunotherapy with PD1 blocking agents has 
again been demonstrated in patients with metastatic melanoma [23]. 
In haematological malignancies, the BM represents not only the site of disease initiation and 
progression, but also a distinctive immunologic microenvironment that contains most 
developing and mature immune cell types, including long-lived CD4+ and CD8+ T cells [24]. A 
recent study identified landmark populations of BM-resident immune cells in mice [25]. Similar 
cells were grouped into clusters according to their expression of the measured proteins. The 
scaffold maps allowed the unsupervised visualisation of the immune composition and 
complexity of murine BMs. In comparison, maps for secondary lymphoid organs exhibited an 
immune landscape dominated by mature T and B lymphocytes, as well as by myeloid cell 
clusters mapping closely to the macrophage and dendritic cell (DC) zones. The integration of 
human mass cytometry data from four healthy donors into the reference map revealed a 
similar overlay pattern between the two species [25]. 
In light of their origin from primary and secondary lymphoid tissues, haematological 
malignancies might be characterised by distinctive mechanisms of immune evasion compared 
with solid tumours [26]. In principle, haematological malignancies are poorly immunogenic and 
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highly immune suppressive. For instance, acute leukaemias disseminate rapidly and constrain 
protective anti-tumour immune responses through a plethora of immune subversive 
mechanisms, including the down-regulation of MHC class I and class II expression, the 
consumption of essential amino acids through arginase-2 (ARG2) [27] and indoleamine 2,3-
dioxygenase-1 (IDO1) [28], the induction of DC dysfunction, the expansion of Treg cells [29] 
and the up-regulation of PD-L1 and other negative checkpoint molecules, such as Cytotoxic 
T-Lymphocyte-associated Antigen-4 (CTLA-4) and Lymphocyte Activation Gene 3 (LAG-3). 
PD-L1 expression might represent a general strategy of immune evasion among aggressive 
B-cell lymphomas [30]. The analysis of formalin-fixed, paraffin-embedded (FFPE) tissue 
biopsies from 237 primary lymphomas has detected PD-L1 protein expression in most nodular 
sclerosis and mixed cellularity classical Hodgkin’s lymphomas (HL), primary mediastinal large 
B-cell lymphomas, Epstein-Barr Virus (EBV)-positive and EBV-negative post-transplantation 
lymphoproliferative disorders and EBV-associated diffuse large B-cell lymphomas (DLBCL). 
This group of neoplasms should then be considered for PD-1/PD-L1-directed therapies, as 
further discussed below. 
Insights into the molecular mechanisms sustaining PD-L1 expression in lymphoma tissues 
have recently been provided [31]. Conditioned media from T-cell and B-cell lymphoma cell 
lines were shown to induce PD-L1/PD-L2 expression on macrophages in a Signal Transducer 
and Activator of Transcription (STAT)-3-dependent manner. In vitro studies pointed to a 
potential role of lymphoma-derived IL-27B in PD-L1/PD-L2 over-expression, suggesting that 
an IL-27/STAT-3 axis might be a target for immunotherapy in patients with NHL. 
 
3. Immune gene signatures 
Innate and adaptive immune responses within the TME can be assessed by gene expression 
profiling [32]. Immune gene signatures, especially those induced by IFN-, are likely to be 
powerful biomarkers of response to checkpoint blockade. A considerable body of scientific 
evidence suggests that tumours responsive to immunotherapies display an inflammatory 
status which is associated with the concomitant counter-activation of immune suppressive 
circuits, thereby reflecting immune escape mechanisms. The implication of these observations 
is that pre-existing immune responses are a pre-requisite for the efficacy of immune 
checkpoint blockade. For instance,  a 10-gene IFN- score, including genes encoding IDO1, 
LAG3, PRF1, GZM and other immune-related genes, showed a significant correlation with 
best overall response (OR) and PFS in patients with advanced melanoma, as well as a non-
significant association with overall survival (OS) [33]. 
Importantly, immune-related gene signatures, and not tumour-related gene expression 
patterns, have been identified as being the main parameters associated with dissemination of 
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CRC to distant metastases [34]. Specifically, patients without synchronous metastasis had a 
significantly increased expression of Th1-related genes, immune cytotoxicity-related genes 
and MHC class II-related genes compared with patients having metastasis at the time of 
diagnosis. This study highlights the concept that immune phenotypes, as measured on the 
basis of multiple parameters, might be a crucial determinant for preventing the metastatic 
dissemination of tumours to distant sites. 
Although immune and genomic landscapes in pre-treatment tumour biopsies correlate with 
response in patients with melanoma and other solid cancers, robust biomarkers that do not 
overlap between responders and non-responders have not yet been identified. An interesting 
study in 53 patients with metastatic melanoma initially treated with CTLA-4 blockade followed 
by programmed death-1 (PD-1) blockade at the time of progression analysed immune gene 
signatures in longitudinal biopsies collected at multiple time points during therapy, using a 12-
marker immunohistochemistry panel and targeted gene expression profiling on a nanoString 
platform [35]. Adaptive immune gene signatures in tumour samples obtained early during 
treatment, including the up-regulation of cytolytic markers, HLA molecules, IFN- pathway 
effector genes and chemokines, were highly predictive of response to immune checkpoint 
blockade. Importantly, unique gene expression profiles observed in the TME of patients 
receiving monotherapy with anti-CTLA-4 or anti-PD-1 antibodies provided insights into the 
mechanisms of response to distinct forms of immune checkpoint blockade, as well as a 
compelling rational for the design of combination immunotherapies. 
The genomic landscape of tumours has been linked with tumour immunity, with neo-antigens 
that are predicted by tumour genome meta-analyses being implicated in driving T-cell 
responses and somatic mutations associated with immunological infiltrates being identified 
[36,37]. A recent analysis of The Cancer Genome Atlas (TCGA) data sets has allowed the 
identification of correlates of immune cytolytic activity in thousands of TCGA solid tumours 
[37]. On the basis of transcript levels of two tightly co-expressed cytolytic effector molecules, 
granzyme A and perforin, differences in cytolytic activities across tumour types were identified, 
with the highest levels being detected in kidney clear cell carcinoma and cervical cancers. 
Interestingly, cytolytic activities and expression of IFN-stimulated chemokines (CXCL9, 
CXCL10 and CXCL11) were associated with the counter-regulatory increase of immune 
suppressive molecules, including IDO1, IDO2, PDL2 and the C1Q complex, and with a 
modest, but significant, pan-cancer survival benefit [37]. 
Finally, immune gene co-expression patterns have been used to identify a subset of high-
confidence marker genes in 9,986 solid tumour samples from TCGA [38]. Immune cell scores 
derived from gene measurements were compared with flow cytometry and IHC data. Cell type 
scores calculated from a list of 60 marker genes measuring 14 immune cell populations were 
concordant with flow cytometry and IHC readings, and allowed comparisons of immune cell 
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abundance across different tumour types. Further analyses in an immunotherapy data set 
(derived from patients receiving anti-CTLA-4 antibodies) showed that cell type gene 
signatures separated responders from non-responders. Importantly, immune cell scores 
represent a convenient technique for extracting critical information on the immune contexture 
of a given tumour in those patients from whom sufficient material for flow cytometry studies is 
not available [38]. 
 
4. Immune biomarkers in haematological malignancies 
The discovery and validation of immune biomarkers is an area of intense investigation. This 
section of the article provides examples of individual immune suppressive molecules that 
could be targeted to improve treatment outcome in patients with leukaemia, lymphoma and 
MM. We will highlight how on-line tools could expand our predictive capabilities [39] and 
support the identification of TME immune gene signatures and key molecular drivers 
implicated in the progression of haematological malignancies, and allow the in-silico validation 
of experimental findings across multiple data sets (Table 1 and Figure 1) [40-42]. 
A pan-cancer resource (PREdiction of Clinical Outcomes from Genomic profiles, PRECOG; 
http://precog.stanford.edu) has recently been developed to identify commonalities in 
prognostic genes from approximately 18,000 human tumours from 166 publicly available 
cancer data sets with survival outcomes across 39 cancer types, including different types of 
haematological malignancies [43]. The statistical associations between genes and clinical 
outcomes were assessed by z-scores, which are directly related to p values and represent the 
number of standard deviations from the mean of a normal distribution. Survival-associated z-
scores for individual studies were combined to yield meta-z-scores for the prognostic 
significance of each gene in each cancer type. One of the two clusters identified was 
associated with inferior clinical outcomes and was functionally linked to cell proliferation [43]. 
However, proliferation genes were not adversely prognostic in AML. The other large tumour 
cluster was associated with favourable survival and was enriched in immunological processes 
and immune-response genes. A new machine-learning tool, known as CIBERSORT [41], was 
subsequently applied to PRECOG data to comprehensively map compositional differences in 
tumour-infiltrating leukocytes in relation to patient outcome. Expression profiles for 22 distinct 
leukocyte subsets were used as input. 
CIBERSORT revealed remarkable differences in relative leukocyte composition between 
haematopoietic and solid tumours. As shown in Figure 2, CIBERSORT inferred high 
frequencies of plasma cells in MM specimens and the predominance of B-cell signatures in 
B-cell malignancies, thereby underpinning its utility for identifying the cell of origin (COO) in 
diverse tumour types [43]. Pooling cancer types allowed the identification of global leukocyte 
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prognostic patterns. Higher frequencies of estimated T-cells, especially intra-tumour  T-
cells, correlated with superior survival. In contrast, infiltration with polymorphonuclear cell 
fractions was the most significant adverse prognostic factor. Finally, signatures of polarised 
M2 macrophages predicted worse clinical outcome than pro-inflammatory M1 macrophages. 
 
Acute myeloid leukaemia. Immune responses are defective in patients with AML due to the 
presence of powerful immune suppressive circuits that are activated by soluble factors and 
immune checkpoint molecules, including PD-L1, TIM-3 and IDO1 [28,44]. Serum kynurenine 
and tryptophan levels at diagnosis, a measure of systemic IDO1 activity, correlate with patient 
outcome [45]. Testing of checkpoint blockade is currently being pursued in patients with AML 
(www.clinicaltrials.gov, NCT02892318; NCT02508870; NCT02532231; NCT02771197; 
NCT03065400; and NCT03066648). Although the mutational burden and immunogenicity of 
AML are inherently low, immunotherapies boosting T-cell functions might be effective, 
especially in the setting of minimal residual disease, and particularly when combined with 
checkpoint inhibition or other strategies to overcome leukaemia-induced immune dysfunction. 
Importantly, genetic mutations such as t(8;21) and inv(16) directly affect the expression of 
CD200 (a suppressor of macrophage and NK cell function) and CD48 (the ligand for the 
activating NK receptor CD244), respectively. 
Chronic lymphocytic leukaemia. Chronic lymphocytic leukemia (CLL) is characterized by 
profound immune defects that are already present in the early stages of the disease and these 
lead to a heightened vulnerability to severe infections. The frequency of PD-L1-expressing 
monocytic MDSCs might be significantly increased in untreated CLL patients compared with 
healthy controls [46]. MDSCs from patients with CLL have been shown to modulate T-cell 
function in vitro and to induce Treg cell differentiation, partly through their expression of IDO1. 
Plasmacytoid DCs, which play an undisputed role in anti-viral immunity as well as anti-
leukaemia responses, are reduced in number and function in patients with CLL as a result of 
decreased expression of FMS-like tyrosine kinase 3 receptor (Flt3) and Toll-like receptor 9 
(TLR9) [47]. These represent molecular targets for restoring immune competency. Functional 
screening assays have identified multiple inhibitory ligands in CLL which impair actin synapse 
formation in T cells, including CD200, CD270, CD274, and CD276 [48]. Importantly, 
lenalidomide, an immune-modulatory drug, can down-regulate tumour cell inhibitory molecule 
expression, thus preventing the induction of T-cell defects. Blockade of the PD1 pathway with 
pembrolizumab has been successfully pursued in patients with CLL and Richter 
transformation into DLBCL [49]. Objective responses were documented in four out of nine 
patients with Richter transformation and in 0 out of 16 patients with relapsed CLL. Analyses 
of pre-treatment tumour specimens showed increased expression of PD-L1 and a trend 
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towards increased expression of PD1 in the TME of patients with confirmed clinical responses. 
All responding patients with Richter transformation had received prior therapy with ibrutinib, a 
Bruton’s tyrosine kinase inhibitor. 
Chronic myeloid leukaemia. Targeted treatment with tyrosine kinase inhibitors (TKIs) has 
revolutionised the fate of patients with chronic myeloid leukaemia (CML). Intriguingly, TKIs 
exert a variety of off-target immunological effects (comprehensively reviewed in ref. [50]), 
suggesting that novel combinations of molecularly targeted agents and immunotherapies may 
further improve clinical success rates for CML. Mass cytometry has enabled the identification 
of prognostic immune biomarkers in longitudinally collected samples from patients with CML 
receiving tyrosine-kinase inhibitors (TKIs) [51]. An increase of circulating CD8+ cytotoxic T 
cells occurred after 7 days of TKI therapy and, importantly, changes in single-cell transduction 
events, including down-regulation of phosphorylated CREB S133 and up-regulation of 
phosphorylated STAT3, reflected molecular response at 3 and 6 months. 
Hodgkin’s lymphoma (HL). Classical HL is characterized by a paucity of malignant 
Hodgkin and Reed-Sternberg (HRS) cells in lymphoid tissues, accompanied by a massive 
infiltrate of reactive cells, including leukocytes and stromal cell types. Modulators of innate 
and adaptive immune responses such as galectin-1 (Gal-1), a member of a highly conserved 
family of carbohydrate-binding proteins, are over-expressed by Reed-Sternberg cells, thereby 
leading to depletion of Th1, Th17 and cytotoxic T cells, with an expansion of Treg cells in the 
TME [52]. Gal-1 levels are elevated in patient serum in association with clinical parameters 
such as Ann Arbor stage, areas of nodal involvement and International Prognostic Score. In 
classical HL, tumour-associated macrophage (TAM) and monocyte signatures in diagnostic 
FFPE lymph node specimens have been associated with high risk of primary treatment failure 
and with decreased PFS and OS [53,54]. Among the 27 individual genes with a discriminative 
power for outcome prediction exceeding that of the best clinical variable (patient age), matrix 
metallopeptidase-1 (MMP1) was over-expressed in patients with treatment failure.  
Non-Hodgkin’s lymphoma (NHL). NHLs are typically associated with chronic inflammatory and 
autoimmune conditions, with severe immune dysregulation being an established risk factor 
and a hallmark of the disease. For instance, high pre-treatment plasma levels of CXCL13, IL-
6 and IL-10 predict worse PFS and OS in patients with AIDS-related NHL (AIDS-NHL) 
receiving intensive multi-agent chemotherapy and immunotherapy with rituximab [55]. 
Longitudinal monitoring of cytokine levels 1 to 5 years preceding NHL diagnosis has identified 
cytokines and other molecules associated with chronic immune activation, such as IL-6, IL-10 
and TNF-, as predictors of the development of systemic AIDS-NHL [56,57]. Similarly, 
circulating levels of B-cell attracting chemokine 1 (BCA-1), soluble TNF receptor 2 and soluble 
vascular endothelial growth factor (VEGF) 2 have been correlated with the risk of NHL in 
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advance of diagnosis [58]. Similarly, genetic variants of toll-like receptor (TLR)-9 which lead 
to increased transcriptional activity in mononuclear cells might increase NHL susceptibility 
[59]. Finally, three independent population-based case-control studies have revealed a 
correlation between NHL risk and single-nucleotide polymorphisms within 12 innate immunity 
genes, including IL-1 receptor antagonist and IgG Fc receptor 2A [60].  
Follicular lymphoma (FL). FL is the second most common type of NHL, accounting for 
approximately 20% of all cases. The malignant B cells in FL are of germinal-centre origin. FL 
is clinically heterogeneous, with some patients experiencing an indolent clinical course and 
others having rapidly progressive disease. A multivariate model of survival was constructed 
using whole-genome microarray data from lymph node tissues from 191 patients with 
untreated FL [61]. This study identified two distinct immune response gene signatures, 
immune-response 1 and immune-response 2, which reflected the biological characteristics of 
the non-malignant immune cells within the biopsy specimens and were molecular predictors 
of the length of survival in patients with FL. The immune-response 1 signature included genes 
associated with T cells and genes which were highly expressed in macrophages. Genes in 
the immune-response 2 signature were preferentially expressed in macrophages and DCs. 
Importantly, the gene expression-based model predicted patient survival independently of 
clinical variables such as the International Prognostic Index (IPI) and the presence or absence 
of B symptoms [61]. 
Other immune cell types, such as tumour-associated mast cells and tumour-associated 
macrophages, have prognostic importance in FL. Mast cell infiltration was detected using 
immunohistochemistry and was shown to negatively affect progression-free survival in 
patients with FL receiving a combination of immunotherapy (rituximab) and chemotherapy 
(CHOP) [62]. The prognostic impact of mast cell infiltration was again independent of the FL 
IPI. The mechanisms by which mast cells reduce the efficacy of antibody-based therapies in 
FL remain to be determined and might include the negative regulation of macrophage activity 
and antibody-dependent cellular cytotoxicity through the expression of Fc receptors which 
can engage rituximab [62]. 
Diffuse large B-cell lymphoma (DLBCL). DLBCL is the most common subtype of NHL, 
representing more than 30% of all adult NHL cases diagnosed in Western countries, and is 
characterised by an aggressive clinical course. In spite of improved response and survival 
rates after the addition of rituximab to the therapeutic armamentarium, up to 40% of patients 
with DLBCL experience relapse and have a poor prognosis. 
Gene expression profiling and next-generation sequencing have been instrumental to the 
identification of molecular subtypes of DLBCL, which are not obviously related to histological 
subtypes of DLBCL and are associated with a remarkable divergence in clinical behaviour. 
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Patients with activated B-cell-like (ABC) gene signatures have a shorter survival compared 
with patients with the other two molecular subtypes, i.e., germinal centre B-cell (GCB) and 
primary mediastinal B-cell lymphoma signatures [63]. Non-GCB type DLBCLs are enriched 
with PD-L1-expressing tumours and might benefit from targeted immunotherapies [64].  
DLBCLs have a heterogeneous immune infiltrate, which includes macrophages, DCs, NK 
cells, T-cell subsets and B cells. Interestingly, pre-treatment gene expression of CD68 as well 
as immunohistochemically-defined CD68+ macrophages might correlate with better outcome 
in patients with DLBCL receiving chemo-immunotherapy, independently of IPI scores or 
molecular subgroups [65]. In contrast, macrophage infiltration was negatively correlated with 
OS in patients treated without rituximab, leading to the hypothesis that rituximab 
administration might switch macrophage profile towards a tumour-promoting phenotype. 
Tissue microarray immunohistochemistry with automated scoring of FoxP3, CD68 and micro-
vessel (CD34) density (MVD) has been shown to stratify patients with DLBCL into risk groups 
and to predict prognosis [66]. Patients in the high-risk group had significantly worse EFS and 
PFS, suggesting that TME components should be considered as an important tool to predict 
patient survival. The NanoString digital hybridization approach for RNA quantification has 
been employed to detect immune effector and checkpoint genes in FFPE biopsies from 
patients with DLBCL [67]. The product of the immune effectors (CD4×CD8) in a ratio with the 
product of checkpoints (PD-L1×M2 macrophages) was used to identify low-immune and high-
immune groupings of patients with significant differences in 4-year survival. Patients with a 
GCB or an ABC molecular subtype of DLBCL and a high immune ratio had a significantly 
extended survival compared with GCB and ABC patients with a low immune ratio, suggesting 
that the balance of anti-tumoural immunity, i.e., the ratio of immune effector cells to negative 
checkpoint molecules, might have an important prognostic value in DLBCL. 
 
Primary mediastinal large B-cell lymphoma (PMLBCL). PMLBCL, a distinct and uncommon 
subtype of DLBCL, is more frequent in young females and originates in the mediastinum, 
presenting with features of local invasion [68]. Aberrations consisting of structural genomic 
rearrangements, missense, nonsense, and frame-shift mutations involving the major 
histocompatibility complex (MHC) class II trans-activator CIITA have been detected in 
approximately 50% of patients with PMLBCL [69]. Genomic lesions in CIITA resulted in 
decreased protein expression and reduction of MHC class II surface expression, favouring the 
establishment of an immune-privileged microenvironment in PMLBCL. 
PMLBCL has a unique transcriptomic signature which is close to classical HL and is 
characterised by constitutive expression of PD-L1 and PD-L2. Amplification and/or 
translocations involving chromosome 9p24.1, a region that includes PDCD1LG2-encoding 
PD-L2, are a common event in PMLBCL but not in DLBCL [70]. This observation entails that 
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PMLBCLs might be susceptible to PD1 blockade. A recent clinical trial run as part of the 
KEYNOTE-013 multi-centre phase 1b study has shown decreases in target lesion in 
approximately 80% of patients evaluable by imaging [71]. Overall, median survival was not 
reached for treated patients. Drug-related adverse effects were observed in 60% of the 
patients and were manageable. Other immune suppressive circuits in patients with PMLBCL 
include the down-regulation of HLA-DR expression and the decrease of cytotoxic CD8+TIA1+ 
T cells, features which correlate with shorter progression-free survival [72]. 
 
Multiple myeloma (MM). Patients with MM suffer from severe and complex defects of humoral 
and cellular immunity, including an increased production of immune suppressive cytokines 
[73] and an expansion of immune regulatory cell types [74]. IL-17, IL-21, IL-22 and IL-23, and 
Th17 cells are increased in patients with MM compared with healthy donors [75]. In particular, 
IL-17 might promote MM growth, colony formation and development in a murine xenograft 
model. 
PD1 and its ligands are broadly expressed in the TME of MM, in which they may mediate 
immune evasion mechanisms [76]. Similarly, PD-L1 expression, as well as IDO1 function, are 
increased in patients with MM compared with healthy controls [77,78]. Of interest, PD-1/PD-
L1 blockade may abrogate bone marrow stromal cell (BMSC)-induced MM growth, an effect 
which is further potentiated by lenalidomide and correlates with the induction of intracellular 
expression of IFN- and granzyme B in effector cells. BMSCs from patients with MM also 
inhibit the lysis of MM cells in a cell contact-dependent fashion by inducing the expression or 
surviving, a caspase-3 inhibitor, and down-regulating CD95 expression [79].  
A thorough characterisation of T-cell, DC and NK cell phenotypes has demonstrated a 
decreased expression of T-cell activation markers, Th1 cells and proliferation markers in 
patients with high-risk ‘smouldering’ MM compared with healthy controls [80]. The fact that 
treatment with the immune modulating drug lenalidomide translated into an increase of 
functionally active T-cells, even when combined with low-dose dexamethasone, suggests that 
immune modulatory drugs might delay the progression of smouldering MM to overt MM.  
Finally, MM can avoid immune surveillance via the transfer of membrane proteins in a process 
known as trogocytosis [81]. For instance, CD86 and HLA-G from malignant plasma cells can 
be acquired by T-cells residing in the BM compartment. HLA-G-expressing T-cells exhibited 
a regulatory potency similar to that of natural Treg cells. Interestingly, the association of CD86 
or HLA-G expression with a poor prognosis suggests the induction of in vivo immune 
suppression. 
 
5. Future immunotherapy approaches for haematological malignancies 
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T-cell engineering with synthetic chimeric antigen receptors (CAR) is revolutionising current 
treatment paradigms for patients with B-cell malignancies. Durable clinical responses up to 24 
months were induced by CD19-directed CAR T cells in 90% of children and adults with 
relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL) [82]. Remissions caused by 
CD19-specific CAR T cells were correlated with high serum levels of IL-15 in patients with 
lymphoma [83]. CD30-specific CAR T cells have been safely and successfully administered 
to patients with HL [84]. Clinical responses to CAR T cells could be improved by targeting 
tumour-induced immune suppression with pembrolizumab [85] or by antagonising IDO1 
activity with lymphodepleting drugs such as fludarabine and cyclophosphamide [86]. 
Innovative approaches are currently being developed to target T-cell malignancies with CD7-
specific CAR T cells [87] and to eradicate antigen-loss relapses of myeloid malignancies with 
dual CD19-CD123-redirected CAR T cells [88]. Anti-myeloma activity of CAR T cells specific 
for B-cell maturation antigen (BCMA) has recently been shown in one patient with 
chemotherapy-resistant disease [89]. Intriguingly, clinical responses have been achieved 
using CD19-specific CAR T cells in one patient with MM despite the absence of CD19 
expression on malignant plasma cells [90]. Finally, a phase I clinical trial in 16 patients with 
relapsed or refractory B-cell malignancies (MM, NHL and CLL) has shown complete clinical 
responses after the infusion of CAR T cells specific for malignancy-associated  light chains 
[91]. 
Bi-specific antibody construct are also being implemented in patients with advanced acute 
leukaemia and with NHLs. Treatment with blinatumomab, a CD3-CD19 bi-specific T-cell 
engager antibody, has resulted in significantly longer median OS than chemotherapy (7.7 
months versus 4.0 months) in a randomised clinical trial in adults with relapsed or refractory 
ALL [92]. Blinatumomab induces the expansion of both naïve and memory CD4+ and CD8+ T 
cells in patients and might skew T-cell receptor repertoires [93]. Immune biomarkers which 
predict clinical responses to blinatumomab have not been identified yet. Interestingly, PD-L1 
expression levels may be higher in children with ALL refractory to blinatumomab [94]. 
Evidence from clinical trials in patients with solid tumours suggests that combination strategies 
that synergise with immune checkpoint blockade might be more effective than single-agent 
immunotherapy, as reviewed elsewhere [95]. It is anticipated that the rational development of 
personalised combination immunotherapy approaches for patients with haematological 
malignancies will be informed by the discovery and validation of immune biomarkers. 
 
6. Multiplexed tissue biomarker imaging 
The direct assessment of immune phenotypes and their spatial relationship by multiplexed 
techniques provides essential information which is highly complementary to gene expression 
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profiling and may allow the discovery of composite predictive biomarkers [32]. 
Multiplexed immunofluorescence allows the detection of up to 30 proteins in regions of interest 
within the TME. Multiple fluorophores can be applied on a single tissue section and are 
interrogated using a multi-spectral microscope [11,96]. This technology enables a 
comprehensive characterization of the topography and spatial relationship between tumour 
cells and microenvironmental cell types, including immune cells. Of relevance, the density of 
CD8+ T-cell infiltrates in the invasive margins of melanoma lesions has been associated with 
expression of the PD1/PD-L1 immune inhibitory axis and with clinical responses to anti-PD-1 
immunotherapy [23]. Quantitative image analysis could also be valuable in dissecting the 
spatial distribution of DCs at different maturation stages within the tumour-draining lymph 
nodes, thus providing insights into actionable circuits of immune dysfunction [97].  
NanoString Technologies (Seattle, USA) has recently developed a multiplexed immune 
profiling approach to measure the expression of up to 800 targets at protein and RNA level on 
a single FFPE tissue slide [98]. This Digital Spatial Profiling platform allows the analysis of 
tumour geography and the delivery of digital counts of biomarker expression with single-cell 
resolution. It is expected that multiplexed technologies can be applied to the investigation of 
immune cell distribution in tissue biopsies from patients with haematological malignancies. 
However, the extensive data that are generated with the use of the above technologies will 
need to be integrated and ‘converted’ into useful information using novel bioinformatics 
approaches. 
 
7. Machine learning 
Advances in bioinformatics have led to a vast amount of data being generated at an 
accelerated pace. Next generation RNA and DNA sequencing methods is providing access to 
incredibly detailed information on entire genomes and allowing us to interrogate more potential 
biomarkers with an increased level of accuracy. This massive volume of data creates a 
problem of complexity which makes it impossible to use traditional methodologies.  
Machine learning is an interdisciplinary field of bioinformatics which employs a data-driven 
class of algorithms to find solutions to a given problem by studying, for example, gene 
expression patterns across many cases / patients. Although widely and successfully used in 
biology and biomarker discovery studies, the use of these approaches in haematological 
malignancy studies has, to date, been extremely limited.  
Many approaches have been developed, each of which will be explained in terms of their utility 
here. These approaches can be broadly characterised in two distinct groups; supervised and 
unsupervised machine learning.  
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6.1 Supervised learning.  
Supervised learning approaches are widely applied and use source features to predict a target 
class  [99]. The supervised approach allows the algorithm to train itself by detecting patterns 
in large datasets that are predictive of the target class, for example, how does IFNG behave 
in acute myeloid leukaemia compared to acute lymphoblastic leukaemia? We can make use 
of previous studies and adjust the algorithm parameters so that it accounts for this information. 
One major advantage is that such approaches are tolerant of the highly complex, non-linear 
and noisy data that are often found in biological systems. 
 
Artificial Neural Networks. Artificial Neural Networks (ANN) are statistical models emulating 
the function of a network of human neurones for the purposes of encapsulating information in 
order to analyse large, complex datasets. The learning process is based on the mathematical 
interconnections between the processing elements that constitute the network architecture 
[100]. This allows them to classify cases based on data by assigning a numerical weight value 
to each input and adjusting them as they sample the data, effectively learning the optimal 
solution. The main advantages of ANNs include their high fault and failure tolerance, scalability 
and consistent generalisation ability, all of which allow them to effectively predict or classify 
new, fuzzy and unlearned data [100,101]. Additionally, they have been recently used to create 
panels of biomarkers that, when used in conjunction with each other, predict breast cancer 
[102]. 
The original ANN architecture, as proposed by Rosenblatt in 1958, was based on the concept 
of a single artificial processing neuron with an activation threshold, adjustable weights and 
bias. However, this could only be used for the classification of linearly separable patterns, as 
it only learns when an error occurs during testing. This is rarely the case with complex 
problems such as cancer, as patients do not typically fall into a standard distribution and 
variance in the data is often significant. Typically, ANNs make use of a Multi-Layer Perceptron 
(MLP) which is made up of multiple perceptrons arranged in layers of three or more, consisting 
of input, hidden and output layers. These consider the predictor variables, perform feature 
detection through an activation function and output the results of the algorithm respectively. 
ANNs have been successfully used to predict and classify data in different contexts, such as 
early detection [103], prediction of long-term survival [104] and biomarker discovery in breast 
cancer [102,105], classification of colorectal cancer tissues [106] and discrimination between 
benign and malignant endothelial lesions [107]. One of the major disadvantages of ANNs is 
their liability to overfit when the parameters have not been optimised. Moreover, they often 
receive criticism for their “black box” approach which allows for little to no interpretation of the 
results and process.   
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Support Vector Machines. Support Vector Machines (SVM) are supervised classification and 
regression algorithms that are primarily designed to solve binary problems. They are focussed 
on finding a hyperplane which separates two classes [108] and have been successfully used 
in pattern recognition and classification. The popularity of SVMs is a result of the availability 
of a large variety of kernels (functions that separate data) which can be broadly split into linear, 
polynomial, sigmoid and radial basis function categories. The greatest advantage of SVMs 
when compared to similar machine learning methods, is that selecting the correct kernel 
function enables the analysis of non-linear data, and overcomes the curse of dimensionality.  
However, the introduction of more features increases the complexity, and therefore the 
computing power required. Notwithstanding the practical issues, SVMs have been used for 
analysing high density data, such as RNA, miRNA and proteomics, and they remain one of 
the most popular classification methods, especially for cancer prediction and prognosis [109-
112]. 
As indicated above, disadvantages of SVMs include the computational processing power and 
the time, although much like ANNs, these problems are quickly being addressed. A more 
crucial issue facing the application of SVMs is choosing the appropriate parameters and kernel 
that will allow for sufficient generalization because of the high algorithmic complexity which is 
required for ‘real’ data. As a result, the use of SVMs is less supported in settings which require 
interpretation and decision-making [108]. 
 
Decision Trees and Random Forests. Tree based methods involve stratifying a dataset into 
multiple categories (similar to hierarchical clustering) that can then be used to predict possible 
outcomes based on the values of the input variables. These methods can be used for both 
classification and regression problems. Decision tree classification algorithms pose a series 
of questions based of the features of the dataset and train to split those features into separate 
categories, thereby resulting in a dendrogram. 
Although the advantages of these methods are that they are computationally efficient, have 
good predictive values and their results are easy to interpret, their predictive accuracy tends 
to be lower than their counterparts. To mitigate this issue, methods such as random forests, 
bagging and boosting are used to construct multiple trees in parallel. These can then be 
combined to provide a significant boost to their prediction accuracy at the cost of some of their 
interpretability. 
Bayesian Networks. Bayes theory states that the conditional probability of A given B is the 
conditional probability of B given A scaled by the relative probability of A compared to B. Using 
Bayesian networks, the association between a set of variables or nodes can be determined 
through joint conditional probability distributions [113]. 
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Although such approaches have been used for multiple biological applications such as 
inferring cellular networks, modelling protein signalling pathways, data integration, genetic 
data analysis and classification [114-116], they are limited by the fact that they need larger 
than average datasets to obtain sufficient prior probabilities to produce an accurate outcome. 
This in turn makes them extremely computationally expensive. Moreover, they tend to perform 
poorly on high dimensional data and their output tends to be complex and as such, can be 
hard to interpret for non-specialists. Finally, it should be noted that Bayesian networks are not 
truly Bayesian in nature. They simply adhere to the basic rules of Bayesian statistics on 
probabilistic inference. It would be more accurate to say that Bayesian networks are directed 
graphical models with Bayesian elements. 
 
6.2 Unsupervised Learning. Unsupervised machine learning approaches are used when the 
desirable or predefined output is not available. The goal of unsupervised learning problems is 
to discover the structure of the data and define groups of similar examples, commonly called 
clustering. Clustering is one of the main unsupervised approaches and it functions by 
assigning data points to natural categorical classes or groups, based on similarity or difference 
of patterns without prior training [117]. 
Unsupervised learning approaches are best used when the subject is a very large dataset with 
few known variables. This allows the user to find natural patterns in the data and discover 
novel groups that have not been previously established and using which training can be 
undertaken. They have been most commonly used to distinguish patterns in microarray data 
by clustering genes based on their expression levels [118-120]. 
 
Hierarchical Clustering. Hierarchical clustering, the most common unsupervised learning 
technique, has been widely used for the analysis of microarray data. It is based on measuring 
distances between data points and defining the first instance of each point as a single cluster, 
followed by merging the clusters according to distance, with smaller distances between 
clusters indicating greater similarity. The process continues in an iterative manner until all 
samples have been used to produce a phylogenetic tree-like structure of the clusters 
(dendrogram), with individual samples at the bottom, and a cluster containing every element 
in the dataset at the top [117]. Some of the most popular methods to determine cluster 
hierarchy include Single-linkage, Complete-linkage, Average-linkage and Centroid distance. 
The major limitation of the hierarchical clustering approach is that as the clusters grow, they 
might not be representative of the objects within, and it is hard to rectify mistakes that occur 
early in the clustering process. 
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K-means Clustering. Much like hierarchical clustering, K-means clustering is a partition 
algorithm which works by arbitrarily grouping objects into a predetermined number of clusters 
in an iterative manner. The centroid-average expression of each cluster is assigned randomly, 
based on the Euclidean distance between each object and the closest cluster average. The 
algorithm then recalculates the average centroid expression, based on the mean of all objects 
assigned to it, and repeats the process until convergence is reached, where the average 
expression of each cluster does not change significantly [117]. Unlike hierarchical clustering, 
this method has the advantage of being able to deal with large datasets and as a result has 
been applied to more complex problems. However, the major drawback of this method is that 
repeating the test can produce significantly different results, as the final assignment of clusters 
is dependent on the initial random assignment of objects [121]. 
 
Principle Component Analysis. Reduction in dimensionality is often necessary for a visual 
inspection of high-dimensional data, as the number of variables being investigated often 
exceed the number of samples. This leads to data points being scarcely distributed in a high 
dimensional feature space [122]. The aim of Principle Component Analysis (PCA) is to map 
the original data into its principle components by linearly transforming the data to reduce 
dimensionality. These principle components are orthogonally arranged, mutually uncorrelated 
linear combinations of the original variables and are often ranked by the amount of variance 
they can explain in the data. The highest ranked components contain most of the relevant 
information, whereas low ranked principle components can be removed if they are not 
required. This approach is often used as a visualisation tool and pre-processing step for 
classification and clustering [117]. 
 
6.3 Novel Approaches. Two bioinformatics approaches developed recently have managed to 
provide novel solutions to common problems related to big data analysis. 
CIBERSORT. CIBERSORT is a platform for characterising the cell composition of tissues 
based on their gene expression profiles [41]. Traditionally, immunohistochemistry and flow 
cytometry have been used to answer such questions and, although highly successful, they 
are limited by their reliance on known markers as well as the fact that these techniques are 
harmful to cells, likely altering the results. CIBERSORT manages to achieve similar results to 
these techniques using the RNA mixtures of the desired tissue. It is an SVM regression 
algorithm which allows the user to differentiate cell types in large datasets. CIBERSORT has 
been proven to have superior performance and be substantially more accurate over traditional 
Machine Leaning methods when the samples studied were unknown, noisy or closely related. 
However, limitations include its reliance on a reference database, the fidelity and size of which 
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are considerable factors in the algorithm’s ability to classify the cell samples, the lack of a p 
values for detection limits and a systematic over- and under-estimation of certain cell types. 
Much like all major machine learning approaches, these problems are being mitigated as more 
computing power becomes available and the size and fidelity of databases increases. 
 
Hive Plots. One of the key challenges in the field of bioinformatics is the issue of visualisation. 
Although the approaches discussed previously have expanded the field of biomarker 
discovery by allowing researchers to consider new possibilities, their use in diagnostics is 
limited by the fact that the results often require expert specialists to interpret. If these 
approaches are to achieve widespread use by clinicians for prognosis, it is paramount to have 
a clear and easily understandable output. Developed by Krzywinski et al. [123], hive plots offer 
an alternative network visualisation method to traditional maps. These maps, usually produced 
by software such as Cytoscape, Gephi, Netminer and more recently, programming languages 
such as R, have a tendency to include an overwhelming amount of information, leading to 
networks that need to be analysed with sorting algorithms to be readable and hard to interpret. 
Moreover, complexity increases exponentially as more information is included. Hive plots offer 
a rational visualisation technique which groups nodes based on specific properties determined 
by the user. The properties can be inherent network statistics, or information such as features 
of clinical data. 
 
8. Expert commentary 
A patient’s immunological profile should be considered a highly dynamic framework, which is 
affected by variations in tumour genetics, epigenetics and micro-RNA expression, age, 
microbiome composition, pharmacological agents and environmental factors including 
infections and exposure to sunlight [21]. There is an emerging need to identify immune 
biomarkers of cancer response to immunotherapies [39]. High-dimensional technologies will 
also enhance our understanding of TME-cancer interactions and will support the prediction of 
therapeutic benefit from immune-based interventions (Figure 3). Immune assays for 
biomarker discovery, as well as sample collection and handling, must be harmonised and 
standardised for investigators to be able to compare and share results [3]. 
Although the role of immune gene signatures in stratifying patients with haematological 
malignancies and in supporting clinical decision making remains to investigated, efforts are 
being devoted to the discovery of prognostic signatures (to predict outcome independent of 
therapy), predictive signatures (to assist in treatment selection according to therapeutic 
effectiveness) and mechanistic immune signatures in patients with solid tumours [124,125]. 
Prognostic signatures help predict outcome independent of therapy, whereas predictive 
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biomarkers and signatures (before treatment) might assist in treatment selection according to 
therapeutic effectiveness. Mechanistic signatures should capture the maximal intensity of 
immune responses which occur in tumour lesions that are about to regress after 
immunotherapy administration [124]. Importantly, comprehensive analyses have indicated 
that prognostic, predictive and mechanistic immune signatures across different 
immunotherapeutic strategies might overlap qualitatively and converge into a common 
pathway [124]. It is becoming evident that solid tumours which are responsive to treatment 
generally have an inflammatory status, indicative of pre-existing immune responses, as well 
as expression of cytolytic markers with concomitant counter-activation of immune suppressive 
and immune escape circuits, which should be targeted with rational combinatorial approaches 
(for instance, PD-L1 blockade coupled with small-molecule IDO1 inhibitors [126]). 
Because of inherent limitations of gene expression profiles, other approaches, such as flow 
cytometry, quantitative immunohistochemistry and next-generation sequencing for T-cell 
antigen receptors or similar technologies (multi-N-plex quantitative PCR, spectratyping and 
immune phenotyping) are recommended to thoroughly characterise the immunological 
landscape of the TME and to establish predictive models [23], as recently reviewed by the 
Immune Biomarkers Task Force of the Society for Immunotherapy of Cancer [11]. 
Conceivably, the analysis of multi-dimensional data sets will be instrumental to mapping the 
immunological landscape of haematological malignancies, to revealing potential immune 
biomarkers and informing the rational design of immune therapies. A combination of 
personalised transcriptomic and proteomic measurements will likely be required to develop 
accurate immune gene signatures in individual patients (Figure 4). The collection of 
comprehensive immunological profiles or ‘cancer-immune set points’ will inform personalised 
clinical trials and support the prediction of anti-cancer responses to immunotherapy [21]. 
 
9. Five-year view 
Immune profiling of patients with haematological malignancies is expected to underpin the 
discovery and validation of new biomarkers, and to foster the clinical implementation of a more 
refined and personalised approach to immune-based interventions. Immune parameters could 
be used to build dynamic frameworks and to support treatment allocation to cancer patients, 
such as the recently proposed ‘cancer immunogram’ [2], the aim of which would be to visualise 
the state of cancer-immune interactions in individual patients with cancer and to discuss 
treatment options in a personalised manner. The information required to build a cancer 
immunogram should include tumour foreignness, patients’ immunological status, evidence for 
tumour infiltration with T cells, expression of checkpoints and other molecules inhibiting T-cell 
function, and tumour cell sensitivity to immune effectors, including the inactivation of antigen 
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processing machinery components [2]. The above parameters should be collected from the 
blood and/or tumour tissues using transcriptomic approaches, high-resolution immune 
phenotyping, spatially-resolved immunohistochemistry and standard immunological assays 
[11].  
Strategies that combine different methods of capturing the immunological status of the TME 
may particularly support the development of composite predictive biomarkers for immune 
checkpoint inhibition in the Haematology clinic, an area that is expected to flourish during the 
next few years [32]. For example, gene expression profiling approaches, such as nanoString 
Technologies’ digital platform [98], coupled with multiplexed immunohistochemistry 
techniques, will allow investigators to quantify mRNA species and multiple proteins expressed 
in cell populations within morphologically defined regions of interest in the TME, thus providing 
crucial information about the topography and spatial localisation of immune cells at different 
tumour stages or after treatment with immunotherapies. 
Finally, new bioinformatics approaches are being developed to unravel the complexity and 
multi-dimensionality of datasets obtained through transcriptomic, sequencing and proteomic 
techniques, to identify responders and non-responders and to stratify and select patients 
based on immune gene signatures in the TME [127]. In the foreseeable future, immune 
biomarkers might guide the development and personalisation of combination immunotherapy 
approaches [10]. As machine learning is becoming an integral part of biomarker discovery, it 
presents its own set of challenges with the first one being the constant need for higher 
computational power. As the size of the available datasets and the complexity of the platform 
technologies (e.g. the move to 1million SNIP probes on a chip, or the advent of RNA deep-
Seq. studies) increases, computational requirements will increase exponentially. While current 
advances in GPU-accelerated parallel computing, solid-state drives and the availability of 
highly parallel cloud computing solutions have allowed for a significant increase in processing 
power, it is proving insufficient to handle some of the more complex questions. There is also 
a trend occurring where the processing power increases so the analyses that are conducted 
become deeper and more detailed. 
The quality and size of the datasets is a key factor in ensuring high quality results. Not only 
have the standards for size been raised, with datasets like METABRIC and databases like 
TCGA, TARGET, ADNI and others providing access to data from thousands of cases, but the 
quality desired in such data is going to keep increasing as well. This is compounded by the 
fact that as more data becomes publically available it can be used to validate tests results with 
ever-increasing accuracy. If comparative analysis is conducted across multiple cancers of 
different tissue origin (so called pan cancer studies) or between the ever-increasing number 
of molecular subtypes of given cancers a greater need for processing will be required. 
Finally, further research is required in the more recent areas of machine learning, primary 
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among them being network inference studies and the so called deep learning and deep mining 
strategies. Understanding how questions of interest interact and affect each other, such as 
how genes regulate each other in a given disease, and use machine learning to model more 
possibilities than could be reasonably studied manually [75] will further increase the potential 
venues of research.  
 
Key issues 
 Identification of predictive/prognostic immune biomarkers in the blood and TME of 
patients with haematological malignancies 
 Development of prognostic and mechanistic immune gene signatures in patients with 
haematological malignancies receiving immunotherapies, including checkpoint 
blockade 
 Handling and analysis of multi-dimensional data sets using artificial neural network 
models 
 Prospective validation and incorporation of immunological parameters into 
personalised routine clinical practice (patient stratification, treatment allocation) 
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Figure and Table Legends. 
 
Figure 1: Identification of potential immune biomarkers using publicly-available on-line tools.  
Blood-Spot (http://servers.binf.ku.dk/bloodspot/) provides plots of gene expression in normal 
and malignant haematopoietic cells at different maturation stages based on curated 
microarray data [128].  We selected MX1 (Myxovirus [Influenza] Resistance 1), an interferon 
(IFN)-inducible gene, as an example of use of Blood-Spot to interrogate human AML data 
sets. Panel A: mRNA expression levels are depicted across a broad range of normal 
haematopoietic differentiation stages (first 11 columns on the left; data derived from Gene 
Expression Omnibus Series GSE42519) and in patients with different cytogenetic subgroups 
of AML (data derived from Gene Expression Omnibus Series 
GSE13159, GSE15434, GSE61804, GSE14468, and from The Cancer Genome Atlas 
[TCGA]). HSC = haematopoietic stem cell; MPP = multi-potential progenitor; CMP = common 
myeloid progenitor; GMP = granulocyte-monocyte progenitor; MEP = megakaryocyte-
erythroid progenitor; PM = promyelocyte; BC = band cell; MM = metamyelocyte; MY = 
myelocyte; MDS = myelodysplastic syndrome; NAN = not available. 
Panel B shows an interactive hierarchical tree summarising the relationship between the 
samples displayed. Expression level are visualized by size and colour of the nodes, as 
intuitively indicated by the colour legend. The full name of cell type abbreviations can be 
obtained by moving the mouse over the individual nodes. Moreover, nodes can be clicked to 
collapse a branch of the tree.  
Panel C shows a survival plot (Kaplan Meier analysis) based on a high-quality AML dataset 
from TCGA. MX1 expression levels were dichotomized (above or below median). Other 
built-in tools allow the removal of cell populations from the graphs, the export of plots as a 
PDF file and the comparison of paired populations in the default expression plots using the 
Student’s t test. 
 
Figure 2: Immune PRECOG; correlation between immune gene expression levels and 
survival in haematological malignancies (https://precog.stanford.edu/about.php). Details 
about available data sets, patient numbers and disease type are provided in panel A. AML = 
acute myeloid leukaemia; B-ALL; B-cell precursor acute lymphoblastic leukaemia; CLL = 
chronic lymphocytic leukaemia; BL = Burkitt lymphoma; DLBCL = diffuse large B-cell 
lymphoma; FL = follicular lymphoma; MM = multiple myeloma. 
Panel B summarises the correlation between publicly available immune gene expression 
levels and overall survival (z-scores). Grey boxes in the heat map denote missing values. The 
22 immune cell populations shown here were identified by Newman and co-workers based on 
the expression of “signature genes” [41,43]. Tfh = follicular helper T cells; Treg = regulatory T 
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cells; DCs = dendritic cells; NK = natural killer. 
Panel C shows two-sided p values that were calculated from z-scores. Green denotes 
correlation with better clinical outcome and red indicates correlation with worse clinical 
outcome. The abundance of immune cell populations was inferred from transcriptomic data 
sets using a recently developed analytical tool (CIBERSORT; (Cell type Identification By 
Estimating Relative Subsets Of known RNA Transcripts). DCs = dendritic cells; NS = not 
significant. 
 
Figure 3: Approaches to immune biomarker discovery in patients with haematological 
malignancies. Blood, bone marrow and lymph node samples should be interrogated using 
genomics and proteomics approaches, immunohistochemistry and flow cytometry to collect 
comprehensive and personalised profiles on neo-antigen expression, topography and 
functional orientation of immune cells, tumour specificity of T cells and prognostic immune 
gene signatures. Lymphoid tissue-resident T cells hold promise as immune effector cells for 
immunotherapy clinical trials, analogous to the tumour-infiltrating T cells from patients with 
melanoma [129], in light of recent evidence that ex vivo-expanded marrow-infiltrating 
lymphocytes (MILs) can be safely administered to patients with high-risk myeloma early after 
autologous CD34-selected haematopoietic stem cell transplantation [130]. Patients on 
immunotherapy clinical trials should be sampled sequentially in order to discover and validate 
mechanistic immune gene signatures associated with response to treatment and/or failure to 
respond. The gut microbiome could be manipulated to optimise immunotherapeutic responses 
to checkpoint blockade, as reviewed elsewhere [131]. 
FFPE = formalin-fixed paraffin-embedded; PBMCs = peripheral blood mononuclear cells; 
MDSCs = myeloid-derived suppressor cells; TAMs = tumour-associated macrophages; DCs 
= dendritic cells; MILs = marrow-infiltrating lymphocytes; IHC = immunohistochemistry; B-reg 
= regulatory B cells; TCRs = T-cell receptors; Th1 = T-helper type 1; IDO1 = indoleamine 2,3-
dioxygenase-1; ARG2 = arginase 2. 
 
Table 1: On-line resources for the meta-analysis of the prognostic value of immune genes in 
patients with haematological malignancies. Several platforms are now available for evaluating 
potential biomarkers (including immune biomarkers) and identifying therapeutic targets in 
patients with haematological malignancies, including PRECOG [43], PrognoScan [40], 
BloodSpot [128] and PROGgeneV2  [42]. The above on-line tools and interfaces allow the 
user to generate Kaplan Meier survival curves and to download gene expression and survival 
data to be subsequently employed for Cox proportional hazard regression analyses and for 
robust validation of the biomarker(s) of interest. Most available data sets encompass 
expression data generated on gene arrays, where individual genes might be represented by 
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multiple probe IDs with potentially different specificity for a given RNA sequence. RNA 
sequencing data do not suffer from this inherent limitation and can be accessed through the 
TCGA data portal [132]. AML = acute myeloid leukaemia; DLBCL = diffuse large B-cell 
lymphoma; FL = follicular lymphoma; RAEB = refractory anaemia with excess of blasts; CLL 
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